A randomised, double-blind, phase 3 study comparing the efficacy and safety of ceftazidime/avibactam plus metronidazole versus meropenem for complicated intra-abdominal infections in hospitalised adults in Asia

•This study was conducted in patients with complicated intra-abdominal infections from Asian hospitals.•Ceftazidime/avibactam plus metronidazole was clinically non-inferior to meropenem.•Efficacy was noted against ceftazidime-susceptible and ceftazidime-non-susceptible pathogens.•No new safety concerns were identified for ceftazidime/avibactam in this study.